Mediterranean Diet and MS: Fatigue Signal, Weak Proof

A Mediterranean-style diet may reduce fatigue and modestly improve quality of life for some people with multiple sclerosis. The best quantitative review found a sizable fatigue signal, but rated the credibility of every dietary comparison very low. That is a reason to study the diet better, not to prescribe it as MS treatment.

For people living with MS, that distinction matters. Disease-modifying therapies can reduce relapses and lesion accumulation, yet fatigue, pain, cognitive problems, bladder and bowel symptoms, and progressive disability often remain. A diet that improves day-to-day symptoms would be useful. It still has to prove that it does.

The strongest summary finds a signal—and a warning label

A 2023 network meta-analysis in Neurology combined 12 randomized trials involving 608 participants and compared eight dietary approaches. Compared with control diets, the Mediterranean diet was associated with lower fatigue, with a standardized mean difference of −0.89 (95% CI, −1.15 to −0.64). It also outperformed control for physical quality of life (SMD 0.47; 95% CI, 0.08 to 0.86) and mental quality of life (SMD 0.36; 95% CI, 0.06 to 0.65).

Those estimates were statistically significant, but the review's own conclusion deserves equal billing: NutriGRADE rated the certainty of all dietary comparisons as very low. Small trials, few studies per comparison, and high or moderate risk of bias can make a pooled result look more precise than the underlying evidence warrants. The review therefore concluded that the evidence did not support dietary recommendations for MS.

Other diets also ranked well for fatigue: low-fat diets had an SMD of −0.90 (95% CI, −1.39 to −0.42), and Paleolithic diets had an SMD of −1.27 (95% CI, −1.81 to −0.74). That does not establish a dietary winner. It shows that small, difficult-to-blind diet trials can produce favorable patient-reported outcomes across several eating patterns.

The largest Mediterranean diet trial found less fatigue, not less disability

The most informative individual Mediterranean diet trial enrolled 147 people with relapsing-remitting MS. In the six-month Bohlouli et al. randomized trial, 68 participants followed a modified Mediterranean diet and 79 followed a traditional Iranian diet. Modified Fatigue Impact Scale scores fell from 72.4 to 63.9 in the Mediterranean-diet group, a change of −8.5 points (P<0.001); the control group had no meaningful change. The estimated effect size was Cohen's d of about 0.54.

The intervention also shifted the Dietary Inflammatory Index from +2.38 to −1.87 (P<0.001), showing that participants changed their reported dietary pattern in the intended direction. But the Expanded Disability Status Scale, an objective disability measure, did not improve significantly in either group.

This is the practical reading of that result: a Mediterranean-style diet may help fatigue, but this trial did not show that it slows MS disability. The trial's effect size was also smaller than the network meta-analysis estimate for fatigue. That gap fits the possibility of small-study effects or publication bias inflating pooled estimates, although it does not prove either explanation.

Progressive MS remains largely unanswered

Progressive MS has fewer effective disease-modifying options, so adjunct approaches would matter greatly. Yet clean dietary evidence in this group is absent. A 2023 single-blind randomized trial enrolled 70 people with progressive forms of MS for four months. Participants received an anti-inflammatory, antioxidant dietary pattern plus synbiotic supplementation, or control care.

The intervention group had a greater reduction in fatigue than the control group (−10.5 versus −0.08 on the MFIS; P<0.001), along with improvements in pain, bladder, bowel, and sexual-function outcomes. The result cannot tell us how much, if any, came from the diet. Synbiotics were given at the same time, and participants knew their group assignments. Expectation effects are especially hard to separate from treatment effects when outcomes rely on symptoms such as fatigue and pain.

A separate 2023 placebo-controlled probiotic trial in 40 people with MS found that Saccharomyces boulardii supplementation lowered high-sensitivity C-reactive protein relative to placebo (P<0.001) and increased total antioxidant capacity (P=0.004) over four months. This supports the idea that gut-directed interventions can alter biomarkers relevant to immune signaling. It does not show that a Mediterranean diet changes the same pathway or treats MS.

Observational studies add context, not confirmation

A 2025 UK MS Register study followed 817 adults for six years and examined whether Mediterranean diet adherence predicted later mental-health and quality-of-life outcomes. Its prospective design improves on a one-time survey because diet precedes the later assessment. Still, it remains observational: people who eat this way may differ in income, disability, physical activity, access to care, or other health behaviors that also affect quality of life.

Cross-sectional studies have the same problem in sharper form. An Italian study found that higher Mediterranean diet adherence was associated with a higher probability of mild-to-moderate MS severity: 6.18-fold (95% CI, 1.44 to 26.59) in the high-adherence group. The finding came from a study of 106 patients, and its wide confidence interval signals limited precision. A 2024 study of 227 older Greek adults with MS also reported associations between Mediterranean diet adherence and disease-related measures, quality of life, and physical activity.

Neither design can resolve reverse causation. Less fatigue and disability can make grocery shopping, cooking, and regular meals easier. In another cross-sectional study of 102 people with MS, Mediterranean Diet Adherence Screener scores were associated with lower fatigue severity, but not with overall MS-related symptom-checklist scores. The mixed result is a useful reminder that association studies do not all point in the same direction.

Why the diet is still reasonable for many people with MS

Mediterranean-style eating emphasizes vegetables, legumes, fruit, whole grains, fish, olive oil, and less red meat. It has stronger evidence outside MS. An umbrella review of prospective cohort evidence linked higher-quality dietary patterns, including Mediterranean-style diets, with lower all-cause mortality, cardiovascular disease, and type 2 diabetes risk. Cardiovascular risk factors can contribute to disability accrual in MS, which makes those broader benefits relevant even if they do not prove an MS-specific effect.

A 2025 study of overweight people with MS also examined three hypocaloric Mediterranean diet patterns and reported improvements in measured and perceived disability. The study explored cardiovascular risk and clinical status, but it does not settle whether weight loss, calorie restriction, macronutrient composition, or Mediterranean dietary features drove the change.

A Mediterranean diet can be a sensible health choice for a person with MS. It is not evidence-based replacement therapy for MS.

What would change the verdict?

Current Mediterranean diet trials in MS include roughly 150 to 200 people with relapsing-remitting disease across two or three short studies, generally lasting three to seven months. No Mediterranean-type intervention trial has exceeded six months. Researchers have not adequately tested whether dietary effects differ by disease-modifying therapy, and studies rarely use objective adherence biomarkers such as plasma carotenoids, omega-3 profiles, or urinary polyphenol metabolites.

Two broader reviews reach the same conclusion as the network meta-analysis: the evidence is insufficient for firm clinical recommendations. A 2023 systematic review of 15 clinical trials totaling 669 participants called for larger, higher-quality trials, and a 2025 RRMS-specific review reported persistent methodological limitations.

The next useful trial would enroll more than 200 participants, run for at least 12 months, measure dietary adherence objectively, include progressive MS in a clean diet-only design, and account for disease-modifying therapy. Until then, Mediterranean eating belongs in the adjunct column: compatible with general health goals, potentially helpful for fatigue and quality of life, and far short of proof that it changes the course of MS.